Vertiflex is a privately held medical device company dedicated to the advancement of minimally invasive solutions for the treatment of lumbar spinal stenosis, which is the leading cause of spinal surgery in the elderly. Founded in 2005 and headquartered in Carlsbad, CA, Vertiflex has developed proprietary, minimally invasive technologies for performing both indirect and direct decompressions of the lumbar spine. These procedures fill the gap in the stenosis treatment continuum between conservative care and traditional spine surgery. To date, Vertiflex has compiled the largest, most rigorous body of device clinical evidence related to lumbar spinal stenosis.
For more information visit:
For more information visit:
Employees: 51-200
Total raised: $54M
Founded date: 2005
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.03.2017 | - | $40M | - |
| 02.02.2011 | - | $14M | - |
Mentions in press and media 7
| Date | Title | Description |
| 15.03.2017 | VertiFlex Raises $40M in Equity Funding | VertiFlex, Inc., a Carlsbad, CA-based developer of advanced, minimally invasive interventions for spinal stenosis, raised $40M in equity funding. The round was co-led by H.I.G. BioHealth Partners and Endeavour Vision with participation from... |
| 08.03.2017 | Vertiflex Finds $40M For Spinal Implants | Carlsbad-based spinal implant developer Vertiflex announced this morning that it has raised $40M in a new funding round, led by Endeavour Vision and H.I.G. BioHealth Partners, and also including New Enterprise Associates; Thomas, McNerney &... |
| 08.03.2017 | Vertiflex Completes $40M Financing Round | Vertiflex, Inc., a Carlsbad, CA-based developer of minimally invasive interventions for spinal stenosis, completed a $40m financing round. The round was led by new investors Endeavour Vision and H.I.G. BioHealth Partners with participation ... |
| 28.05.2015 | NIH study shows why HIV drugs should be given earlier, Juno Therapeutics in $737M deal with Editas Medicine (Morning Read) | “We now have clear-cut proof that it is of significantly greater health benefit to an HIV-infected person to start antiretroviral therapy sooner rather than later…Moreover, early therapy conveys a double benefit, not only improving the heal... |
| 08.05.2015 | Medtech execs: Thinking about reimbursement early is key to a successful launch | At a time when the regulatory barriers put up by the Food and Drug Administration seem to be easing a bit, Medtech companies are still facing challenges bringing new products to market, a panel at the Medtech Investing Conference 2015 in Mi... |
| 02.02.2011 | VertiFlex Completes $14M Equity Financing | VertiFlex®, Inc., a San Clemente, CA-based developer of percutaneous and motion preserving spinal surgery technologies, completed a $14m equity financing with provision for an additional $14m investment within twelve months. Existing invest... |
| - | NIH study shows why HIV drugs should be given earlier, Juno Therapeutics in $737M deal with Editas Medicine (Morning Read) | TOP STORIES A multiyear, randomized clinical trial study of 4,685 patients with HIV in 35 countries found that early treatment — when patients are initially diagnosed — can cut in half the number of cases of AIDS, deaths and complications, ... |